Reblozyl® (luspatercept-aamt) – New orphan drug approval
November 8, 2019 - The FDA announced the approval of Celgene and Acceleron’s Reblozyl (luspatercept-aamt), for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Download PDF
